Compare SPOK & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | XGN |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.2M | 253.9M |
| IPO Year | 1992 | 2019 |
| Metric | SPOK | XGN |
|---|---|---|
| Price | $13.02 | $7.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 164.6K | ★ 365.9K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.60% | N/A |
| EPS Growth | ★ 12.68 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $139,739,000.00 | $63,599,000.00 |
| Revenue This Year | $4.11 | $22.50 |
| Revenue Next Year | $2.63 | $14.75 |
| P/E Ratio | $16.27 | ★ N/A |
| Revenue Growth | 1.47 | ★ 14.08 |
| 52 Week Low | $12.26 | $2.67 |
| 52 Week High | $19.31 | $12.23 |
| Indicator | SPOK | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 27.83 |
| Support Level | $12.91 | $7.01 |
| Resistance Level | $13.25 | $7.60 |
| Average True Range (ATR) | 0.33 | 0.39 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 43.82 | 11.03 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.